Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases [1] - The company's lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis, respectively [1] - Vidofludimus calcium has demonstrated therapeutic activity in phase 2 trials for relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis [1] Product Pipeline - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and additional anti-inflammatory and anti-viral effects by inhibiting dihydroorotate dehydrogenase (DHODH) [1] - IMU-856 targets Sirtuin 6 (SIRT6) to restore intestinal barrier function and regenerate bowel epithelium, with potential applications in gastrointestinal diseases such as celiac disease and inflammatory bowel disease [1] - IMU-381 is a next-generation molecule in preclinical testing aimed at addressing gastrointestinal diseases [1] Upcoming Conferences - Immunic will participate in the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5-9, 2025, in San Diego, California, with management and medical teams available at booth 2233 [3] - At the German Biotech Days 2025 on April 9-10, 2025, Chief Scientific Officer Hella Kohlhof will present on vidofludimus calcium, highlighting its dual benefits of neuroprotection and relapse prevention [3] - The presentation will be part of a symposium titled "All Grown Up? Mature Biotech Companies Present their Progress" on April 9, 2025 [3]